Vibostolimab binds to TIGIT and blocks the interaction between TIGIT and its ligands (CD112 and CD155). Activation helps T lymphocytes destroy tumor cells and can be used for the treatment of NSCLC and melanoma. Here, PVR is linked to neoplasm.